Mazdutide

Investigated uses

• Obesity and type 2 diabetes in clinical development.

Mechanism and hypotheses

• Mazdutide is a dual GLP-1/glucagon receptor agonist evaluated in randomized obesity trials.
• Hypothesized: Long-term cardiovascular and rare-event safety remain under study.

Human evidence

• Randomized phase 2 and phase 3 trials in Chinese adults found clinically meaningful dose-dependent weight reduction compared with placebo. Limitations: Population, sponsor product, duration and regional regulatory context limit transfer to other formulations and populations.

Safety highlights

• Gastrointestinal adverse events were the dominant treatment-emergent events in randomized obesity studies.
• Rare-event, cardiovascular and long-term glucagon-pathway risks remain incompletely characterized.

Regulatory context

No FDA-approved product matching the exact catalog presentation was identified in this review.